<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905149</url>
  </required_header>
  <id_info>
    <org_study_id>IBMS-SPB</org_study_id>
    <nct_id>NCT02905149</nct_id>
  </id_info>
  <brief_title>Impact of the Serratus Plane Block in Pain and the Use of Opioids in Breast Surgery</brief_title>
  <official_title>Impact of the Serratus Plane Block in Pain and the Use of Opioids in Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to evaluate the analgesic efficacy of a regional anesthesia
      technique ( interfascial block at the serratus muscle) performed in patient undergoing breast
      surgery and the effect of this technique on postoperative analgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regional analgesia techniques have shown to have benefits over conventional analgesia. The
      lower opioids analgesics requirements decrease side effects associated with the use of this
      type of medication. It is also increasingly established scientific evidence that reducing
      opioids administration may play a role in prognosis of cancer patients given the
      immunosuppressive effect of these drugs.

      In patients undergoing oncologic/reconstructive breast surgery paravertebral block has been
      traditionally performed, however the paravertebral space lacks a clear anatomical barrier
      from the spinal cord so the drugs administered can diffuse to the intervertebral foramen
      causing deeper levels of blocks (epidural or spinal blocks) and injections at the
      paravertebral level are associated with serious complications both neurological and
      respiratory (meningitis, spinal hematomas abscesses, pneumothorax, respiratory failure. This
      has led to the development of less invasive technique with an improved safety profile.

      The serratus plane block falls within the framework of these newly developed techniques and
      the present study aims to assess its role in the management of the patient undergoing cancer
      / reconstructive surgery.

      Considering a decrease in postoperative morphine consumption of 40% and the average
      consumption of opioid after breast surgery under general anesthesia is 15 milligrams (
      standard deviation 8 mg ) investigators calculated that with an alpha error 5% power 80 % 56
      patients (28 per group) were required to achieve a significant result. In anticipation of
      possible loss of sample, 60 patients were recruited . Analysis will be performed by intention
      to treat.

      Quantitative variables (opioid consumption, pain estimated by VAS scale) will be analyzed
      using mixed linear model adding a random variable for interindividual variability for pain
      threshold. If the data do not meet the criteria of normality the Mann-Whitney U test will be
      used. If the groups differ in preoperative variables. Investigators will make a multivariable
      analysis adjusting for these variables. The need for rescue analgesia over time is analyzed
      by Kaplan-Meier curve where the terminal state is the administration of the first dose of
      opioid postoperatively. The difference side effects (nausea, pruritus, apnea, urinary
      retention, ileus ) and complications IPO questionnaire and analyzed by chi-square test and
      Fisher exact test. Scheffe correction will be applied for multiple comparison. Missing data
      are excluded from analysis.

      The study has planned data monitoring and auditing by the IIS la Fe according to AEMPS
      guidelines. Registries will be obtained from electronic medical records available for double
      check procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2016</start_date>
  <completion_date type="Actual">July 8, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two group parallel arm. With study group receiving regional anesthestic block with levobupivacaine and control group receiving standard care with intravenous analgesia only</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Opioid Usage</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Total opioid usage in the first 24 hours (intra and postoperative) (in morphine milligrmas, fentanyl/morphine conversion = 10 mcgs/1mg). Opioid used will be fentanyl and morphine. Fentanyl will be converted in morphine milligrams equivlents to caluclate the total first 24H dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at Rest and Coughing</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Pain at rest and coughing at 24h postoperative (Visual analogue scale 0-10 with 0 meaning no pain and 10 meaning the worst imaginable pain). High score mean worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Opioid Administration on the Ward</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Time to first opioid administration on the ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Opioid Related Complications</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>presence of nausea/vomit or apnea or urinary retention or ileus is assessed. It is a dicothomic composite (yes or no).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Surgery</condition>
  <condition>Breast Reconstruction</condition>
  <arm_group>
    <arm_group_label>Serrato</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard anesthesia+serratus plane block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serrato</intervention_name>
    <description>Serratus plane block.</description>
    <arm_group_label>Serrato</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Standard anesthesia</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years, undergoing oncological surgery and/or breast
             reconstruction surgery whose pathology and surgical intervention supose at least a 24
             hours hospital admission

        Exclusion Criteria:

          -  ASA Physical Status Classification System- IV.- Morbid obesity (Body mass index &gt;40).
             -Impossibility of anatomical structures ultrasound identification in a satisfactory
             way (there can be no distinction in the interfascial plane between serratus and
             pectoral muscle). -Opioids treatment before surgery. Sepsis and/or infection at the
             puncture site.

          -  Haemostasis disorders. - Allergy to any of the drugs used in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Mazzinari</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación Sanitaria La Fe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <results_first_submitted>October 21, 2019</results_first_submitted>
  <results_first_submitted_qc>February 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2020</results_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncological</keyword>
  <keyword>Surgery</keyword>
  <keyword>Breast</keyword>
  <keyword>Reconstruction</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02905149/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Serrato</title>
          <description>Standard anesthesia+serratus plane block.
Serrato: Serratus plane block.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Standard anesthesia
Control: Standard anesthesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Serrato</title>
          <description>Standard anesthesia+serratus plane block.
Serrato: Serratus plane block.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Standard anesthesia
Control: Standard anesthesia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Opioid Usage</title>
        <description>Total opioid usage in the first 24 hours (intra and postoperative) (in morphine milligrmas, fentanyl/morphine conversion = 10 mcgs/1mg). Opioid used will be fentanyl and morphine. Fentanyl will be converted in morphine milligrams equivlents to caluclate the total first 24H dose.</description>
        <time_frame>First 24 hours after surgery</time_frame>
        <population>2 participants were lost to follow up because of malfunctioning of the electronic device administering the potoperative opioid</population>
        <group_list>
          <group group_id="O1">
            <title>Serrato</title>
            <description>Standard anesthesia+serratus plane block.
Serrato: Serratus plane block.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard anesthesia
Control: Standard anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Usage</title>
          <description>Total opioid usage in the first 24 hours (intra and postoperative) (in morphine milligrmas, fentanyl/morphine conversion = 10 mcgs/1mg). Opioid used will be fentanyl and morphine. Fentanyl will be converted in morphine milligrams equivlents to caluclate the total first 24H dose.</description>
          <population>2 participants were lost to follow up because of malfunctioning of the electronic device administering the potoperative opioid</population>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="17" upper_limit="24"/>
                    <measurement group_id="O2" value="30" lower_limit="26" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <p_value_desc>Not adjusted for multiple comparison</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
            <estimate_desc>Generalized Hodges-Lehmann median difference is used. These are robust to the possibility that the population distributions in the two groups are different in ways other than location. It may not represent the raw median difference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain at Rest and Coughing</title>
        <description>Pain at rest and coughing at 24h postoperative (Visual analogue scale 0-10 with 0 meaning no pain and 10 meaning the worst imaginable pain). High score mean worse outcomes</description>
        <time_frame>First 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serrato</title>
            <description>Standard anesthesia+serratus plane block.
Serrato: Serratus plane block.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard anesthesia
Control: Standard anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain at Rest and Coughing</title>
          <description>Pain at rest and coughing at 24h postoperative (Visual analogue scale 0-10 with 0 meaning no pain and 10 meaning the worst imaginable pain). High score mean worse outcomes</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Worst pain in 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Least pain in 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain interf. with activities in bed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain interf. with breathing or coughing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opioid Administration on the Ward</title>
        <description>Time to first opioid administration on the ward</description>
        <time_frame>First 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serrato</title>
            <description>Standard anesthesia+serratus plane block.
Serrato: Serratus plane block.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard anesthesia
Control: Standard anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opioid Administration on the Ward</title>
          <description>Time to first opioid administration on the ward</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.95" lower_limit="4.61" upper_limit="11.28"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.8" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Opioid Related Complications</title>
        <description>presence of nausea/vomit or apnea or urinary retention or ileus is assessed. It is a dicothomic composite (yes or no).</description>
        <time_frame>First 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serrato</title>
            <description>Standard anesthesia+serratus plane block.
Serrato: Serratus plane block.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard anesthesia
Control: Standard anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Opioid Related Complications</title>
          <description>presence of nausea/vomit or apnea or urinary retention or ileus is assessed. It is a dicothomic composite (yes or no).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Serrato</title>
          <description>Standard anesthesia+serratus plane block.
Serrato: Serratus plane block.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Standard anesthesia
Control: Standard anesthesia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The blinding method cannot entirely exclude ascertainment bias.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Maria Cortell</name_or_title>
      <organization>Instituto de Investigación Sanitaria La Fe</organization>
      <phone>961246611</phone>
      <email>investigacion_clinica@iislafe.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

